% | $
Quotes you view appear here for quick access.

Мабвакс Терапевтика Message Board

dr_cisla 1 post  |  Last Activity: Jan 21, 2016 5:10 AM Member since: Jun 21, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Moronic market

    by aladdin_new Jan 20, 2016 9:48 AM
    dr_cisla dr_cisla Jan 21, 2016 5:10 AM Flag

    : Novocure results 'remarkable,' says JMP Securities
    JMP Securities believes that the 14.9 month mean overall survival rate demonstrated by Novocure's (NVCR) pancreatic cancer treatment is "remarkable." The firm notes that Celgene's (CELG) Abraxane obtained FDA approval after the overall survival rate of patients taking it increased to 8.5 months. The firm keeps a $43 price target and Outperform rating on NovoCure.